Amantadine Hydrochloride

SHANGHAI, May 19, 2025 – WinHealth Pharma Group (WinHealth Pharma) and Merz Therapeutics announced the signing of an enhanced long-term strategic partnership agreement, representing a significant milestone in their longstanding collaboration. This expanded agreement strengthens their strategic presence in the Greater China region and reaffirms their shared commitment to advancing access to innovative, high-quality therapies for a broader patient population.This strategic collaboration ushers in the next phase of partnership between WinHealth Pharma and Merz Therapeutics, advancing into the "2.0 Era". The collaboration has achieved a historic breakthrough in both depth and breadth. The partnership term has been substantially extended, and the product portfolio has been expanded from two to five key offerings, covering prescription medicines, over-the-counter (OTC) products, consumer health brands, and cross-border business. Furthermore, the geographic reach has been broadened from Mainland of China to China’s Hong Kong, Macau, and Taiwan, further extending access to innovative therapies for a larger patient population. This upgrade underscores the profound trust and mutual commitment between both companies, highlighting their unwavering dedication to sustainable, long-term growth in Greater China.At the strategic partnership signing ceremony, the leadership teams from WinHealth Pharma and Merz Therapeutics took a group photoThrough this collaboration, the two companies will further build on their successful partnership in Mainland of China, capitalizing on the proven success of Hepa-Merz® (Ornithine Aspartate Injection) and Contractubex® (Compound Heparin Sodium and Allantoin Gel), while expanding the commercialization rights of these products to China’s Hong Kong, Macau, and Taiwan. The partnership is further solidified with the introduction of new products, including the dermatology OTC brand Contractubex® (Compound Heparin Sodium and Allantoin Gel), PK-Merz® (Amantadine/Amantadine Sulfate) for Parkinson’s disease, and the renowned Pantogar® series for anti-hair loss. This strategic expansion further enriches and strengthens WinHealth Pharma’s portfolio, broadening its reach across prescription medicines, over-the-counter (OTC) products, and consumer health segments.• Hepa-Merz® (Ornithine Aspartate Injection): As an originator therapy, Hepa-Merz® is widely recommended by both domestic and international clinical guidelines as a first-line treatment for hepatic encephalopathy.• Contractubex® (Compound Heparin Sodium and Allantoin Gel): Known for its anti-inflammatory, moisturizing, and wound-healing properties, it is recommended in both domestic and international guidelines for the treatment of scars.• Contractubex® (Compound Heparin Sodium and Allantoin Gel): A leading OTC dermatology brand, Contractubex® Scar Gel is widely used in over 60 countries and is highly recommended by healthcare professionals for scar treatment.• PK-Merz® (Amantadine/Amantadine Sulfate): Used in the treatment of Parkinson’s disease, PK-Merz® helps improve motor symptoms by compensating for neurotransmitter imbalances in the brain and is effective in preventing and treating dyskinesia.• Pantogar® Series Anti-Hair Loss Products: Including capsules, shampoo, and tonic, these products enhance hair growth and provide essential nutrients, treating diffuse hair loss and supporting the natural growth of hair.This expanded collaboration not only solidifies WinHealth Pharma's leadership in the dermatology, hepatology, and neurology therapeutic areas but also injects new momentum into the company's strategic initiatives, driving its continued growth in Greater China and beyond.Andrea von der Lippe, President Region International Markets at Merz Therapeutics, said: "Since the inception of our partnership with WinHealth Pharma in 2017, we have achieved outstanding results. WinHealth Pharma has proven its exceptional commercialization capabilities, extensive market reach, and superior execution, establishing itself as a trusted long-term strategic partner. The deepening of this strategic collaboration not only builds on the strong foundation of our past successes but also paves the way for exciting new opportunities and broader development prospects in the Greater China market. We look forward to continuing our close collaboration with WinHealth Pharma to bring more established and innovative products to market, offering an even broader range of advanced therapeutic options for a wider patient base."Carlos Sese, Senior Director Head of Region APAC at Merz Therapeutics, said: "Our collaboration with WinHealth Pharma is built on a strong foundation of deep trust and a shared vision. We have maintained a close partnership and worked together to successfully bring several key products to market. The further deepening of this strategic partnership not only solidifies our position in Greater China but also opens up a new chapter for future business expansion and the introduction of innovative therapies. This upgrade of our strategic collaboration is not just an extension of our past successes, but a catalyst for unleashing our future potential. We look forward to continuing our close partnership with WinHealth Pharma, driving the development and commercialization of more groundbreaking therapies to meet the increasingly diverse treatment needs of patients."Jack Wang, Chairman of Hong Kong WinHealth Pharma Group, said: " The deepening of our strategic partnership with Merz Therapeutics is a landmark achievement, marking a new chapter in our collaboration across Greater China and unlocking unprecedented opportunities for growth. As a leading biopharmaceutical company with an integrated value chain, WinHealth Pharma remains committed to a patients-first philosophy, concentrating on the development and commercialization of innovative and originator drugs, while addressing the unmet medical needs in the healthcare sector. This strategic advancement will accelerate our market penetration and growth in Greater China, enhance our portfolio in critical therapeutic areas such as hepatology, neurology, and dermatology, driving our continued growth in Asia and global markets. Our unwavering commitment is to deliver groundbreaking therapies that significantly improve patient outcomes and quality of life, paving the way for a broader and brighter future."Oliver Hao, Executive Director and Co-CEO of Hong Kong WinHealth Pharma Group, said: "At WinHealth Pharma, we remain steadfast in our commitment to patients, partners, and employees, which is deeply rooted in our founding principles and corporate mission, driving our sustainable growth on a global scale continuously. This collaboration marks the commencement of a new ‘2.0 era’ in our strategic partnership with Merz Therapeutics. In this new model, both companies are committed to forging a deeper and more long-term collaboration that will not only benefit more patients across Greater China but will also significantly expand the reach and influence of the brands within the partnership’s scope. Moving forward, WinHealth Pharma remains focused on introducing more originator and innovative therapies, providing patients with more effective and accessible treatment options, enhancing their quality of life, and resolutely upholding our patient-centered development strategy."About Merz TherapeuticsMerz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.Please visit www.stage.merztherapeutics.com.About WinHealth PharmaFounded in 2006, WinHealth Pharma is a Hong Kong-based biopharmaceutical company with a comprehensive, end-to-end value chain. The company focuses on three core areas: proprietary pharmaceutical products, CSO business, and specialty care, with a strong commitment to the development and commercialization of cutting-edge medicines. Guided by a patient-first philosophy, we are dedicated to delivering breakthrough therapies and innovative healthcare solutions to patients with cardio-renal diseases, hematologic cancers, gastrointestinal diseases, respiratory and infectious diseases, rare diseases, and other unmet medical needs. Our commitment is to improve patients’ lives through transformative treatments. With a well-established presence in China, WinHealth Pharma is actively expanding across Asia and other international markets, building a comprehensive healthcare ecosystem, driving innovation, and addressing the evolving treatment needs of patients. For more information, please visit www.winhealth.hk.END